BRPI0707559B8 - polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos - Google Patents

polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos

Info

Publication number
BRPI0707559B8
BRPI0707559B8 BRPI0707559A BRPI0707559A BRPI0707559B8 BR PI0707559 B8 BRPI0707559 B8 BR PI0707559B8 BR PI0707559 A BRPI0707559 A BR PI0707559A BR PI0707559 A BRPI0707559 A BR PI0707559A BR PI0707559 B8 BRPI0707559 B8 BR PI0707559B8
Authority
BR
Brazil
Prior art keywords
hydroxy
dihydroquinolin
piperidin
ethylamino
biphenyl
Prior art date
Application number
BRPI0707559A
Other languages
English (en)
Inventor
Kennedy Andrew
Patrick Mallet Franck
Jane Kindon Leanda
Chudasama Reshma
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707559(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0707559A2 publication Critical patent/BRPI0707559A2/pt
Publication of BRPI0707559A8 publication Critical patent/BRPI0707559A8/pt
Publication of BRPI0707559B1 publication Critical patent/BRPI0707559B1/pt
Publication of BRPI0707559B8 publication Critical patent/BRPI0707559B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Abstract

composto, composição farmacêutica, combinação, métodos para tratar um distúrbio pulmonar, para produzir broncodilatação em um paciente, e para tratar doença pulmonar obstrutiva crônica ou asma, usos de um composto e de uma combinação, e, processo para preparar um composto. um sal de ácido succínico de 1- [2-(2-cloro-4- { [(r)-2-hidróxi-2-(8-hidróxi-2-oxo-1,2-diidroquinolin-5 -il)etilamino] metil]}-5 -metoxifenil-carbamoil)etil] piperidin-4-il éster do ácido bifenil-2-ilcarbâmico e ou um solvato do mesmo, para uso no tratamento de distúrbios pulmonares".
BRPI0707559A 2006-02-10 2007-02-08 polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos BRPI0707559B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound
GB0602778.3 2006-02-10
PCT/EP2007/051196 WO2007090859A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [ (r)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) eth ylaminoimethyl] } -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Publications (4)

Publication Number Publication Date
BRPI0707559A2 BRPI0707559A2 (pt) 2011-05-10
BRPI0707559A8 BRPI0707559A8 (pt) 2019-01-29
BRPI0707559B1 BRPI0707559B1 (pt) 2021-01-12
BRPI0707559B8 true BRPI0707559B8 (pt) 2021-05-25

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707559A BRPI0707559B8 (pt) 2006-02-10 2007-02-08 polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos

Country Status (33)

Country Link
US (1) US7960551B2 (pt)
EP (1) EP1981872B1 (pt)
JP (1) JP5616021B2 (pt)
KR (1) KR101488691B1 (pt)
CN (1) CN101379057B (pt)
AR (2) AR059409A1 (pt)
AU (1) AU2007213767B2 (pt)
BR (1) BRPI0707559B8 (pt)
CA (1) CA2641769C (pt)
CR (1) CR10227A (pt)
CY (1) CY1119238T1 (pt)
DK (1) DK1981872T3 (pt)
EA (1) EA016580B1 (pt)
ES (1) ES2640226T3 (pt)
GB (1) GB0602778D0 (pt)
HR (1) HRP20171304T1 (pt)
HU (1) HUE034315T2 (pt)
IL (1) IL193103A (pt)
JO (1) JO3389B1 (pt)
LT (1) LT1981872T (pt)
MA (1) MA30273B1 (pt)
MY (1) MY153656A (pt)
NO (1) NO341343B1 (pt)
NZ (1) NZ570242A (pt)
PE (2) PE20110120A1 (pt)
PL (1) PL1981872T3 (pt)
PT (1) PT1981872T (pt)
SG (1) SG169404A1 (pt)
SI (1) SI1981872T1 (pt)
TW (1) TWI401251B (pt)
UA (1) UA100364C2 (pt)
WO (1) WO2007090859A1 (pt)
ZA (1) ZA200806782B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013562B1 (pt) 2009-04-14 2021-08-03 Glaxo Group Limited Processo para a preparação do composto, e, composto
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PL3210981T3 (pl) 2009-04-23 2019-06-28 Theravance Respiratory Company, Llc Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
BR112014002593B1 (pt) * 2011-08-02 2022-11-29 Alfasigma S.p.A Composição farmacêutica de avidina oxidada apropriada para inalação e kits relacionados
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EA201500651A1 (ru) * 2012-12-18 2015-11-30 Альмираль, С.А. НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022776A (en) * 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
NZ251687A (en) 1992-03-31 1995-12-21 Glaxo Group Ltd Oxadiazol- and thiadiazol- phenylcarbamates and -phenylureas and pharmaceutical compositions thereof
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
US6130232A (en) 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
SG80041A1 (en) 1998-06-08 2001-04-17 Advanced Medicine Inc Muscarinic receptor antagonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
JP2003516390A (ja) 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
AU6233201A (en) 2000-06-05 2001-12-17 Byk Gulden Lomberg Chem Fab Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
PE20020719A1 (es) 2000-12-22 2002-10-11 Almirall Prodesfarma Ag Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
CN1646527A (zh) 2002-04-12 2005-07-27 贝林格尔英格海姆法玛两合公司 包含β模拟剂(BETAMIMETICS)及新颖抗胆碱酯酶的药物
US6747043B2 (en) * 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
WO2004106333A1 (en) * 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
EP1685118B1 (en) * 2003-11-21 2009-07-08 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
GB0602778D0 (en) 2006-03-22
LT1981872T (lt) 2017-09-11
HUE034315T2 (en) 2018-02-28
CN101379057B (zh) 2013-02-13
PT1981872T (pt) 2017-09-13
CA2641769C (en) 2014-02-04
UA100364C2 (xx) 2012-12-25
SG169404A1 (en) 2011-03-30
EA200801691A1 (ru) 2009-02-27
CA2641769A1 (en) 2007-08-16
IL193103A0 (en) 2009-02-11
PL1981872T3 (pl) 2017-11-30
US20070281971A1 (en) 2007-12-06
CR10227A (es) 2008-10-29
ES2640226T3 (es) 2017-11-02
NZ570242A (en) 2011-09-30
JO3389B1 (ar) 2019-03-13
ZA200806782B (en) 2009-10-28
BRPI0707559A2 (pt) 2011-05-10
NO20083425L (no) 2008-09-09
MA30273B1 (fr) 2009-03-02
BRPI0707559B1 (pt) 2021-01-12
TWI401251B (zh) 2013-07-11
JP2009526018A (ja) 2009-07-16
EA016580B1 (ru) 2012-06-29
CN101379057A (zh) 2009-03-04
AR059409A1 (es) 2008-04-09
EP1981872A1 (en) 2008-10-22
IL193103A (en) 2013-06-27
US7960551B2 (en) 2011-06-14
KR101488691B1 (ko) 2015-02-02
SI1981872T1 (sl) 2017-10-30
MY153656A (en) 2015-03-13
AU2007213767B2 (en) 2012-04-26
TW200800948A (en) 2008-01-01
KR20080114723A (ko) 2008-12-31
PE20110120A1 (es) 2011-03-08
PE20071249A1 (es) 2008-01-16
HRP20171304T1 (hr) 2017-10-20
CY1119238T1 (el) 2018-02-14
NO341343B1 (no) 2017-10-16
DK1981872T3 (en) 2017-09-11
AU2007213767A1 (en) 2007-08-16
WO2007090859A1 (en) 2007-08-16
JP5616021B2 (ja) 2014-10-29
AR104288A2 (es) 2017-07-12
EP1981872B1 (en) 2017-06-21
BRPI0707559A8 (pt) 2019-01-29

Similar Documents

Publication Publication Date Title
BRPI0707559B8 (pt) polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos
BRPI0514413C1 (pt) sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento
BRPI0509245A (pt) cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócito
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
WO2010018109A3 (en) Substituted aminotetralines
IL210577A (en) Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation
WO2010018113A3 (en) Bi-aryl aminotetralines
BRPI1009022A2 (pt) "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI1011593A2 (pt) "combinação farmacêutica, composição farmaceuticamente aceitavél, e, método para tratar um distúrbio metabólico, para tratar doença pulmonar obstrutiva crônica, e para tratar ou prevenir um ou mais distúrbios metabólicos."
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
EA200970435A1 (ru) Лечение общих расстройств развития
AR098785A2 (es) DERIVADOS DE BIFENILO AGONISTAS DE RECEPTORES ANDRENÉRGICOS b₂ Y ANTAGONISTAS DE RECEPTORES MUSCARÍNICOS
WO2010018112A3 (en) Monoaryl aminotetralines
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2013085849A3 (en) Sulfate esters of noribogaine
CL2013000870A1 (es) Solvato de isopropanol e hidrato de la sal oxalato cristalina del 1-(2-([4-(4-([(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil)fenilcarbamoil)butil]metilcarbamoil)etilpiperidin-4-il ester del acido bifenil-2-ilcarbamico; composicion farmaceutica; y uso para tratar una enfermedad pulmonar, epoc y asma.
JP2017531692A5 (pt)
EP1902715A3 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
HK1129071A1 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2007109615A3 (en) β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
WO2008014247A3 (en) 4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders
WO2007115092A3 (en) 10-substituted cytisine derivatives and methods of use thereof
MA28990B1 (fr) Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF